Attention-deficit-hyperactivity disorder (ADHD) affects over 40 million people—children, adolescents, and adults—across the major pharmaceutical markets. The key treatment goals for both…
MARKET OUTLOOK The accelerated approvals of Kymriah (Novartis) for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and Yescarta (Kite…
The treatment of axial spondyloarthritis has been transformed in the last decade by the approval of biologics to treat the disease and the recognition that patients without evidence of radiographic…
Market Outlook Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s Velcade are the cornerstones of therapy for multiple myeloma. Successive label expansions have driven significant…
Overall, the renal anemia therapy market will expand over the 2017-2027 study period, fueled by the increasing prevalence of this complication of chronic kidney disease and the emergence of a novel…
MARKET OUTLOOK DRG anticipates the next ten years to be an exciting time in the hemophilia A space as the number of treatment options grow for patients with, and without, inhibitors. The…
Patients with osteoporosis are at increased risk of suffering fractures due to a loss in bone strength. These fractures, in turn, place a considerable burden on public health systems. The…
PsA, a disease characterized by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly understood, underdiagnosed, and undertreated. Nevertheless, TNF…
Pulmonary hypertension (PH) is a devastating disease, for which there is no cure. Despite the rarity of the disease, the potential commercial rewards from drugs approved for it are considerable,…
Bipolar disorder (BPD) is a spectrum disorder that encompasses two symptom domains: mania and depression. BPD treatment is usually initiated with atypical antipsychotics and antiepileptic drugs (…
Biomarker-driven prescribing continues to play an increasingly prominent role in key oncology indications. Biomarkers play an important role and are well-entrenched in indications such as non-small…
Market Outlook This report examines the market access factors that influence the success of therapies for chronic heart failure (CHF), with a special focus on payers’ and cardiologists’…
Market Outlook Biomarker-driven prescribing continues to play an increasingly prominent role in key oncology indications. Biomarkers play an important role and are well-entrenched in indications…
Dyslipidemia refers to abnormalities in the composition, concentration, or size of lipids and lipoproteins in the circulation, and it is a key modifiable risk factor for cardiovascular (CV) disease…
MARKET OUTLOOK The Crohn’s disease(CD) therapy market will continue to evolve over the next decade. The well-established TNF-α inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s…
